Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs LIGNOSPAN STANDARD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.
Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.
Local and regional infiltration anesthesia,Peripheral nerve blocks,Dental anesthesia
Local or regional anesthesia for dental procedures,Local infiltration anesthesia,Nerve block anesthesia
Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.
2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.
Terminal elimination half-life is approximately 2-3 hours in adults. In neonates, half-life is prolonged (8-10 hours due to immature hepatic function). Clinical context: Short half-life reduces risk of systemic accumulation with repeated doses.
Terminal elimination half-life is approximately 1.5–2 hours in adults. Prolonged in hepatic impairment or heart failure.
Primarily hepatic via N-demethylation by CYP1A2; minor metabolism by CYP3A4. Metabolites excreted renally.
Primarily metabolized by CYP3A4 to monoethylglycinexylidide and glycinexylidide; also undergoes deethylation and hydrolysis.
Mepivacaine is primarily metabolized in the liver via N-demethylation and hydroxylation. Less than 5% is excreted unchanged in urine. Hepatic clearance accounts for >90% of elimination; renal excretion of metabolites accounts for the remainder. Fecal elimination is minimal (<2%).
Primarily hepatic metabolism; <10% excreted unchanged in urine. Biliary/fecal excretion is minimal.
Approximately 75-85% bound to alpha-1-acid glycoprotein (orosomucoid) and less extensively to albumin. Binding is concentration-dependent.
Approximately 65% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and albumin.
Volume of distribution (Vd) is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution. Higher Vd in infants (2-3 L/kg) due to larger extracellular fluid compartment.
Volume of distribution (Vd) is approximately 0.6–1.0 L/kg. Reflects extensive tissue distribution.
Mepivacaine is not administered orally due to extensive first-pass metabolism. For local infiltration or regional administration, bioavailability is essentially 100% at the site of administration. Intravenous bioavailability is 100% by definition.
Bioavailability: ~100% for intravenous; approximately 85–90% for intramuscular; negligible after oral administration due to extensive first-pass metabolism.
GFR ≥ 50 m L/min: no adjustment. GFR 30-49 m L/min: consider reducing dose by 25% due to potential accumulation of metabolites. GFR < 30 m L/min: avoid or use with caution; reduce dose by 50% and monitor for CNS toxicity.
No dose adjustment required for lidocaine; however, caution in severe renal impairment due to potential accumulation of metabolites. GFR <30 m L/min: monitor for toxicity.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: contraindicated due to impaired metabolism and risk of toxicity.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated or use with extreme caution; reduce dose by 75% and monitor levels.
Children: 1.1-1.8 mg/kg mepivacaine (0.54-0.9 mg/lb) as 2% solution with 1:20,000 levonordefrin; maximum 4.4 mg/kg (not exceeding 300 mg). For example, 20 kg child: 22-36 mg mepivacaine (1.1-1.8 m L of 2% solution).
Lidocaine 2% with epinephrine: 0.5-2.5 mg/kg per dose (max 4.5 mg/kg lidocaine, epinephrine max 0.01 m L/kg of 1:100,000 solution). For infiltration: 1-2 m L/kg of 0.5-1% solution (without epinephrine in young infants).
Elderly patients (≥65 years): use lowest effective dose due to increased sensitivity, potential renal impairment, and comorbidities. Maximum single dose: 4.4 mg/kg (not exceeding 300 mg); reduce dose by 50% if GFR < 50 m L/min. Monitor cardiovascular status due to levonordefrin.
Reduce initial doses due to decreased hepatic clearance and increased sensitivity; use lowest effective dose. Maximum single dose: 200 mg lidocaine (without epinephrine) or 300 mg (with epinephrine). Monitor for CNS and cardiac toxicity.
Not available.
Not available.
Risk of central nervous system toxicity (seizures, CNS depression),Cardiovascular toxicity (arrhythmias, hypotension) with high doses or rapid absorption,Avoid in patients with severe liver disease,May cause methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency
Excessive blood levels may cause CNS and cardiovascular toxicity; use lowest effective dose; caution in patients with hepatic disease, cardiac disease, or epilepsy; monitor for signs of systemic toxicity.
Hypersensitivity to mepivacaine or other amide-type local anesthetics,Severe hypotension or cardiogenic shock,Porphyria,Administration via intravenous regional anesthesia (Bier block)
Hypersensitivity to lidocaine or amide-type anesthetics; severe hypotension; myasthenia gravis; severe heart block; untreated hypovolemia.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as concurrent MAO-A inhibition from levonordefrin may cause hypertensive crisis. Limit caffeine intake (stimulant additive effect on heart rate).
No significant food interactions. Avoid citrus fruits or acidic foods immediately after injection as they may irritate the injection site.
Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses, but no well-controlled human studies exist. Levonordefrin is a vasoconstrictor; systemic absorption may reduce uterine blood flow, potentially causing fetal hypoxia. Risk in the first trimester is unknown; second and third trimester use may be associated with fetal bradycardia and acidosis if high doses are administered or inadvertent intravascular injection occurs. Use only if clearly needed.
Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies, but human data are limited. Epinephrine may cause uterine vasoconstriction and reduce placental blood flow, especially in high doses or with inadvertent intravascular injection. During the first trimester, risk is minimal with standard doses. In the second and third trimesters, no known increased risk of malformations. During labor and delivery, high doses or repeated administration may lead to fetal bradycardia or neonatal depression due to lidocaine accumulation.
Mepivacaine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 0.4-0.6. Levonordefrin is not expected to enter breast milk significantly. The American Academy of Pediatrics considers mepivacaine compatible with breastfeeding. However, observe the infant for signs of local anesthetic toxicity (e.g., drowsiness, irritability).
Lidocaine is excreted into breast milk in small quantities, with an estimated M/P ratio of approximately 0.4. The relative infant dose via breast milk is less than 4% of the maternal weight-adjusted dose and is considered compatible with breastfeeding. Epinephrine is not orally bioavailable. Lignospan standard is safe for use during lactation with appropriate dosing.
No specific dose adjustment is recommended for mepivacaine in pregnancy; however, plasma levels of mepivacaine may be lower due to increased volume of distribution and clearance. Use the lowest effective dose and avoid high doses or frequent administration to minimize fetal exposure. Levonordefrin dose should be limited to minimize vasoconstriction effects.
Pregnancy may increase lidocaine clearance due to increased hepatic blood flow and volume of distribution, but no dose adjustment is recommended for standard local anesthetic doses. However, reduced doses may be necessary in patients with preeclampsia or impaired placental perfusion. Epinephrine dose should be minimized to avoid uterine vasoconstriction.
For dental procedures, limit dose to 1 cartridge (1.8 m L) per appointment due to levonordefrin's α-adrenergic effects. Avoid in patients with sulfite allergy (bisulfite preservative). Use with caution in severe cardiovascular disease, pheochromocytoma, or hyperthyroidism due to levonordefrin. Onset 2-3 min, duration 60-90 min (infiltration).
Lignospan Standard is a 2% lidocaine with 1:100,000 epinephrine dental anesthetic. Aspiration before injection is critical to prevent intravascular administration. Avoid use in patients with severe heart block, uncontrolled hypertension, or hyperthyroidism due to epinephrine. Maximum dose: 4.4 mg/kg lidocaine (0.7 mg/kg epinephrine). Use with caution in patients on MAOIs, tricyclic antidepressants, or beta-blockers due to potential hypertensive crisis or reduced heart rate.
Report any history of heart disease, high blood pressure, or sulfite allergy before injection.,You may feel temporary increased heart rate or palpitations due to the vasoconstrictor.,Numbness may last several hours; avoid chewing gum or eating until sensation returns.,Seek immediate medical attention if you experience chest pain, severe headache, or difficulty breathing.,Use only as directed by your dentist; do not exceed prescribed dose.
Avoid eating or drinking until numbness wears off to prevent accidental biting of tongue or cheek.,Do not operate machinery or drive for at least 30 minutes after injection.,Apply ice to injection site if swelling occurs; report persistent pain or infection.,Inform your dentist of all medications, especially those for depression, high blood pressure, or heart problems.
"Concomitant use of prochlorperazine and mepivacaine may lead to additive central nervous system (CNS) depression, resulting in excessive sedation, respiratory depression, and increased risk of hypotension. Mepivacaine, a local anesthetic, can cause CNS excitation followed by depression, while prochlorperazine, a phenothiazine antipsychotic, directly depresses CNS function. This combination may also potentiate cardiotoxicity, including QT prolongation and arrhythmias, due to additive effects on cardiac conduction."
"Mepivacaine, an amide local anesthetic, and Dezocine, a mixed opioid agonist-antagonist, both exhibit dose-dependent central nervous system (CNS) depressant and respiratory depressant effects. When co-administered, additive or supra-additive CNS and respiratory depression can occur, leading to increased risk of sedation, confusion, respiratory depression, and potentially coma or apnea, particularly in patients with compromised respiratory function or those receiving high doses of either agent."
"The combination of gamma-hydroxybutyric acid (GHB) and mepivacaine can lead to additive central nervous system (CNS) depression and respiratory depression. Both drugs act as CNS depressants, with GHB enhancing GABAergic activity and mepivacaine blocking sodium channels, which may result in severe sedation, respiratory arrest, and hypotension. Concomitant use requires careful risk-benefit assessment and close monitoring."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs LIGNOSPAN STANDARD, answered by our medical review team.
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.. LIGNOSPAN STANDARD is a Local Anesthetic with Vasoconstrictor that works by Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN and LIGNOSPAN STANDARD depend on the specific clinical indication. These are both Local Anesthetic with Vasoconstrictor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.. The standard adult dose of LIGNOSPAN STANDARD is: 2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN and LIGNOSPAN STANDARD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses,. LIGNOSPAN STANDARD is classified as Category C. Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.